- Silence Therapeutics to Present at Jefferies Global Healthcare Conference
- Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
More ▼
Key statistics
On Thursday, Silence Therapeutics PLC (SLNCF:PKC) closed at 7.60, -30.28% below its 52-week high of 10.90, set on Mar 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.60 |
---|---|
High | 7.60 |
Low | 7.60 |
Bid | -- |
Offer | -- |
Previous close | 7.60 |
Average volume | 432.67 |
---|---|
Shares outstanding | 46.66m |
Free float | 5.45m |
P/E (TTM) | -- |
Market cap | 979.39m USD |
EPS (TTM) | -0.3911 USD |
Data delayed at least 15 minutes, as of May 30 2024 16:14 BST.
More ▼